Pricing a medical device in Europe is not a marketing exercise — it is the single decision that determines whether regulatory compliance costs, post-market surveillance obligations, and country-by-country distribution margins can all be absorbed while leaving enough gross margin to fund the next round. Most MedTech startups price too low because they benchmark against software. The result is structurally unprofitable companies that burn out before PMS obligations mature.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • MedTech pricing must cover ongoing MDR obligations — PMS under Articles 83–86, vigilance under Articles 87–92, and QMS maintenance under Article 10 — not just COGS and sales margin.
  • A MedTech gross margin below roughly 60% is structurally dangerous for most startups because it leaves no room for regulatory surveillance, reimbursement dossier work, and the slow-moving European payer cycle.
  • European pricing is not one price — it is a negotiated matrix across hospital tenders, statutory insurance, private insurance, self-pay, and multi-country distributor agreements.
  • Setting a low "intro price" to win early customers almost always traps the company: payer reference pricing, hospital framework contracts, and distributor margin expectations are extremely hard to raise later.
  • The funding model is downstream of pricing. VC-backable MedTech requires a price point and margin profile that can absorb a 24–60 month sales cycle.

Why this matters

Felix has sat in pitch meetings where founders present a beautifully engineered device, a credible MDR strategy, and a price point that would make the company unprofitable even at fantasy market share. When asked how they arrived at the price, the answer is some version of: "We benchmarked against the closest competitor and went 20% below." Every time, that answer signals a company that has not thought about pricing as a strategic instrument — only as a competitive one.

Pricing in European MedTech is where regulatory reality, payer reality, and founder optimism collide. The regulation sets a cost floor you cannot escape: the true cost of CE marking is only the beginning. Post-market surveillance, PSUR updates, vigilance handling, annual Notified Body surveillance audits, and eventual recertification all have to be paid for from gross margin, every year, for the life of the product. If the list price does not support that, nothing else in the business plan matters.

What MDR actually says (and what it implies for pricing)

MDR does not set prices. But it creates a fixed set of obligations whose costs must be recovered through pricing, and it is worth naming them explicitly because they are often missing from founder financial models.

Article 5 — Placing on the market: devices must meet the General Safety and Performance Requirements in Annex I throughout their lifetime. Lifetime obligation, not one-time obligation.

Article 10 — General obligations of manufacturers, including the requirement in Article 10(9) to establish, document, implement, maintain, keep up to date, and continually improve a quality management system. The QMS is a permanent cost center. EN ISO 13485:2016+A11:2021 certification and surveillance audits run annually.

Article 83 — Post-market surveillance system: every manufacturer must plan, establish, document, implement, maintain, and update a PMS system proportionate to the risk class and appropriate for the type of device. Annex III defines the technical documentation for the PMS system.

Article 87–92 — Vigilance: serious incident reporting, FSCAs, trend reporting. Each of these has staffing and process costs attached.

The practical translation: every unit you sell has to contribute not just to COGS and sales commission, but to an ongoing regulatory overhead that is not optional and does not decrease over time. For a Class IIa device, that overhead typically runs in the low six figures EUR per year as a floor, even for very small portfolios. For Class IIb and Class III, it is higher. Your gross margin has to cover that line before anything else is paid for.

A worked example

A German startup sells a Class IIa reusable diagnostic device. COGS is EUR 180. They are tempted to price at EUR 450 — a "friendly" 2.5x markup to win early hospital pilots.

Run the numbers against reality:

  • Gross margin at EUR 450: 60% (EUR 270 per unit).
  • Annual unit volume in year 3: realistic estimate 1,200 units.
  • Annual gross margin pool: EUR 324,000.

Now subtract the non-negotiable regulatory overhead: - Notified Body surveillance audit: EUR 15,000–25,000 - QMS software and document control: EUR 12,000 - PRRC (fractional or in-house): EUR 30,000–80,000 - PMS data collection and PSUR updates: EUR 20,000–50,000 - Clinical evaluation updates: EUR 15,000–40,000 - Vigilance system and complaint handling: EUR 10,000–30,000 - Eudamed maintenance and UDI management: EUR 5,000–15,000

Low-end total: EUR 107,000. High-end: EUR 252,000.

Leftover from gross margin pool for everything else (R&D, sales, marketing, G&A, founder salaries): between EUR 72,000 and EUR 217,000. That is not a company. That is an expensive hobby.

Now rerun at EUR 650 per unit with the same COGS. Gross margin per unit: EUR 470. Annual gross margin pool: EUR 564,000. After regulatory overhead: EUR 312,000 to EUR 457,000. That is a company — still tight, still demanding disciplined execution, but viable.

The difference between EUR 450 and EUR 650 is not "20% more revenue." It is the difference between a company that can fund its own PMS obligations and one that cannot.

The Subtract to Ship playbook

1. Start from the regulatory overhead, not from the competitor. Calculate your annual fixed regulatory cost floor before you touch a price number. That floor plus realistic sales, G&A, and a target operating margin is your minimum viable gross margin pool. Back-solve from there.

2. Aim for 70%+ gross margin, accept 60% as the hard floor. Below 60% gross margin, a Class II MedTech startup is structurally at risk. Above 70%, you have room to negotiate, to survive long sales cycles, and to fund surveillance. This is not arbitrary — it reflects the fixed-cost reality of regulated products.

3. Do not anchor low. The single most damaging pricing mistake is a low intro price to win a reference hospital. Once that price enters a hospital procurement system, it becomes the ceiling for every subsequent customer in that country and often across borders via payer reference pricing databases. You can discount below list price for strategic customers. You almost cannot raise list price later.

4. Price by value, not by cost-plus. For a diagnostic that saves two hours of radiologist time per study, the value calculation is straightforward. For a therapeutic device that avoids a second surgery, the value calculation is enormous. Anchor pricing conversations with payers on avoided cost and clinical outcome, not on your BOM.

5. Build a country matrix, not a single price. Germany (statutory insurance, G-BA pathways, DRG integration), France (LPPR listing, HAS evaluation), Nordics (regional procurement), Italy and Spain (regional health services with heavy budget constraints), UK (NHS, NICE) — these are not one market. Your list price can be uniform. Your realized ASP will not be. Plan for 15–35% variance across countries from day one.

6. Negotiate with decision-making units, not with buyers. In hospital sales, the procurement officer negotiates price. The clinical department decides whether to adopt. The finance department decides whether the reimbursement covers it. Ignore any one of them and you lose the deal. This connects directly to the decision-making units for MedTech sales.

7. Use distributors with eyes open. Distributor margins in Europe typically run 25–45% depending on country and class. If your list price is EUR 650, your realized revenue through a distributor may be EUR 360–490. Build that into the original pricing model, not as a late correction.

8. Revisit pricing only at deliberate moments. The right moments: new clinical evidence (post-market data that strengthens value claim), regulatory milestones (new indications), payer coverage expansion, major competitor exit. The wrong moment: every time sales slows.

Reality Check

  1. Do you know your gross margin at current list price, and does it exceed 60%?
  2. Have you calculated your annual regulatory overhead floor (Notified Body + QMS + PMS + PRRC + clinical evaluation updates + vigilance)?
  3. Does your annual gross margin pool at realistic year-3 volume cover that floor with at least 2x headroom?
  4. Is your list price above or below the clinical value it delivers — and can you quantify that value in payer terms?
  5. Do you have a country-by-country pricing matrix, or a single "European price"?
  6. Have you modeled distributor margin into your realized ASP, or only into your list price?
  7. Is your fundraising narrative consistent with a 24–60 month European sales cycle at your current price?
  8. If your three largest customers asked for a 15% discount tomorrow, would your model still support PMS obligations?

Frequently Asked Questions

Why is software-style pricing dangerous in MedTech? Software benchmarks assume near-zero marginal cost and near-zero ongoing regulatory burden. MedTech has real COGS per unit and real annual regulatory overhead per product family. Pricing a physical device or a regulated SaMD like consumer SaaS ignores both, which is why so many pre-revenue MedTech startups discover they cannot sustain their own business at scale.

Should I match my biggest competitor's price? Rarely. Large competitors have amortized regulatory overhead across broad portfolios and achieved COGS through scale you do not have. Matching their price with your cost structure means you are subsidizing the customer's adoption out of your runway.

What is a reasonable gross margin target for a Class IIa device? 65–75% is a reasonable target range for a Class IIa device where a startup can realistically sustain operations, fund PMS, and attract follow-on capital. Below 60% is the danger zone.

How do I raise prices after launching low? Slowly, painfully, and usually through product versioning. The clean path is to keep the current product at the current price and introduce a new version (with new features or a new clinical claim) at the higher target price. Direct price increases on the same SKU trigger procurement reviews in most European hospitals.

Does reimbursement set my price? Reimbursement constrains your price but rarely sets it directly. In Germany, DRG integration defines the envelope the hospital has to work within. In France, LPPR listing defines the reimbursed amount. Your list price lives inside those envelopes. See health insurance reimbursement in Europe for the mechanics.

How does pricing connect to my funding story? Directly. Investors back business models that can sustain themselves at scale. A low-price, low-margin MedTech with Class IIa or higher regulatory burden is not a VC story — the numbers do not close. Price is the hinge.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 5, Article 10, Article 83, Articles 87–92, Annex I, Annex III.
  2. EN ISO 13485:2016+A11:2021 — Medical devices — Quality management systems.
  3. MDCG 2025-10 (December 2025) — Post-market surveillance guidance.